LOGIN  |  REGISTER
Terns Pharmaceuticals
Compass Therapeutics

Option Care Health Announces Financial Results For The First Quarter Ended March 31, 2023

May 03, 2023 | Last Trade: US$22.15 0.27 1.23

BANNOCKBURN, Ill., May 3, 2023 /PRNewswire/ -- Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2023.

First Quarter 2023 Financial Results and Highlights

  • Net revenue of $1,015.8 million, up 10.9% compared to $915.8 million in the first quarter of 2022
  • Gross profit of $229.0 million, or 22.5% of net revenue, up 14.0% compared to $200.9 million, or 21.9% of net revenue, in the first quarter of 2022
  • Net income of $39.2 million, or $0.22 basic earnings per share, up 29.5% compared to net income of $30.3 million, or $0.17 basics earnings per share, in the first quarter of 2022
  • Adjusted EBITDA of $93.8 million, up 20.6% compared to $77.8 million in the first quarter of 2022
  • Cash flow from operations of $89.8 million compared to $32.7 million in the first quarter of 2022
  • Cash and cash equivalents balance was $297.8 million at the end of the first quarter of 2023
  • Completed stock repurchase of approximately $75.0 million
  • Launched Naven Health, the national infusion nursing platform founded in the acquisitions of Infinity Infusion Nursing and Specialty Pharmacy Nursing Network
  • Received the 2023 Gallup Exceptional Workplace Award

John C. Rademacher, Chief Executive Officer, commented, "The Option Care Health team's commitment to providing extraordinary patient care in the post-acute and ambulatory setting delivered another quarter of strong financial results. As we look to the balance of the year, our focus is on continuing to execute on our mission to transform healthcare by providing innovative services that improve outcomes, reduce costs and deliver hope for patients and their families."

Mike Shapiro, Chief Financial Officer, commented, "We are very pleased with the results we delivered in the first quarter. Based on this momentum, we are increasing our earnings outlook for the full year."

Mr. Shapiro continued, "Acute revenue continued to perform well this quarter as we build upon our reputation as a trusted and dependable partner to health systems. Our stable chronic patient census and double digit chronic revenue growth also contributed to outperformance in a quarter that is typically lower in consolidated revenue. In addition, we drove considerable clinical labor leverage as a result of efficient utilization of our infusion suite network, in which approximately 26% of our nursing visits occurred in the quarter. Moreover, our procurement strategies and disciplined cost management enabled us to expand Adjusted EBITDA margins to over nine percent in the quarter."

Updated Full Year 2023 Financial Guidance

For the full year 2023, Option Care Health expects to generate:

  • Net Revenue of $4.15 billion to $4.375 billion
  • Adjusted EBITDA of $380 million to $395 million
  • Cash Flow from Operations of at least $240 million

Additionally, the Company continues to anticipate an effective tax rate of 27% - 29% and net interest expense of approximately $61.0 million to $65.0 million.

The foregoing full year 2023 financial guidance excludes the impact of the Company's pending combination with Amedisys, Inc. ("Amedisys").

Conference Call

In a separate press release issued today, Option Care Health announced it has entered into a definitive agreement to combine with Amedisys, a leading provider of healthcare in the home.

Option Care Health and Amedisys will host an investor conference call today at 5:30 p.m. EDT to discuss the details of the transaction. Details for such call are available in the separate press release issued today. In light of the transaction announcement, we will forego our previously scheduled first quarter of fiscal 2023 earnings conference call.

About Option Care Health

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

Investor Contacts

Mike Shapiro

Bob East, Asher Dewhurst, Jordan Kohnstam

Chief Financial Officer

Westwicke

T:  (312) 940-2538

T:  (413) 213-0500

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements - Safe Harbor

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long–lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health's business operations and facilitates comparisons to the Company's historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

Schedule 1

 

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)(UNAUDITED)

 
    
 

March 31,

 

December 31,

 

2023

 

2022

    

ASSETS

   

CURRENT ASSETS:

   

   Cash and cash equivalents

$                    297,776

 

$                    294,186

   Accounts receivable, net

395,209

 

377,542

   Inventories

249,643

 

224,281

   Prepaid expenses and other current assets

86,908

 

98,330

Total current assets

1,029,536

 

994,339

    

NONCURRENT ASSETS:

   

   Property and equipment, net

105,571

 

108,321

   Intangible assets, net

21,677

 

22,371

   Referral sources, net

334,001

 

341,744

   Goodwill

1,533,569

 

1,533,424

   Other noncurrent assets

106,048

 

112,737

Total noncurrent assets

2,100,866

 

2,118,597

TOTAL ASSETS

$                 3,130,402

 

$                 3,112,936

    

LIABILITIES AND STOCKHOLDERS' EQUITY

   

CURRENT LIABILITIES:

   

Accounts payable

$                    448,890

 

$                    378,763

Other current liabilities

169,676

 

186,588

 Total current liabilities

618,566

 

565,351

    

NONCURRENT LIABILITIES:

   

Long-term debt, net of discount, deferred financing costs and current portion

1,057,787

 

1,058,204

Other noncurrent liabilities

103,830

 

103,278

 Total noncurrent liabilities

1,161,617

 

1,161,482

 Total liabilities

1,780,183

 

1,726,833

    

STOCKHOLDERS' EQUITY

1,350,219

 

1,386,103

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$                 3,130,402

 

$                 3,112,936

Schedule 2

 

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

 
  
 

Three Months Ended
March 31,

 

2023

 

2022

NET REVENUE

$     1,015,848

 

$        915,784

COST OF REVENUE

786,843

 

714,848

GROSS PROFIT

229,005

 

200,936

    

OPERATING COSTS AND EXPENSES:

   

Selling, general and administrative expenses

147,866

 

133,969

Depreciation and amortization expense

14,514

 

14,722

  Total operating expenses

162,380

 

148,691

OPERATING INCOME

66,625

 

52,245

    

OTHER INCOME (EXPENSE):

   

Interest expense, net

(13,834)

 

(12,246)

Other, net

1,438

 

1,269

  Total other expense

(12,396)

 

(10,977)

    

INCOME BEFORE INCOME TAXES

54,229

 

41,268

INCOME TAX EXPENSE

15,021

 

10,993

NET INCOME

$          39,208

 

$          30,275

    

Earnings per share, basic

$              0.22

 

$              0.17

Earnings per share, diluted

$              0.21

 

$              0.17

    

Weighted average common shares outstanding, basic

181,262

 

179,961

Weighted average common shares outstanding, diluted

182,735

 

181,681

Schedule 3

 

OPTION CARE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)(UNAUDITED)

 
 
 

Three Months Ended
March 31,

 

2023

 

2022

CASH FLOWS FROM OPERATING ACTIVITIES:

   

Net income

$          39,208

 

$          30,275

Adjustments to reconcile net income to net cash provided by operations:

   

  Depreciation and amortization expense

15,225

 

15,979

  Other non-cash adjustments

22,498

 

21,131

  Changes in operating assets and liabilities:

   

  Accounts receivable, net

(17,812)

 

(28,766)

  Inventories

(25,362)

 

(34,089)

  Accounts payable

70,127

 

76,872

  Other

(14,132)

 

(48,721)

  Net cash provided by operating activities

89,752

 

32,681

    

CASH FLOWS FROM INVESTING ACTIVITIES:

   

Acquisition of property and equipment

(5,760)

 

(5,359)

  Net cash used in investing activities

(5,760)

 

(5,359)

    

CASH FLOWS FROM FINANCING ACTIVITIES:

   

Purchase of company stock

(75,000)

 

Other financing cash flows

(5,402)

 

(1,145)

  Net cash used in financing activities

(80,402)

 

(1,145)

NET INCREASE IN CASH AND CASH EQUIVALENTS

3,590

 

26,177

Cash and cash equivalents - beginning of the period

294,186

 

119,423

CASH AND CASH EQUIVALENTS - END OF PERIOD

$        297,776

 

$        145,600

Schedule 4

 

OPTION CARE HEALTH, INC.

QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES

(IN THOUSANDS)(UNAUDITED)

 
  
 

Three Months Ended
March 31,

 

2023

 

2022

Net income

$          39,208

 

$          30,275

Interest expense, net

13,834

 

12,246

Income tax expense

15,021

 

10,993

Depreciation and amortization expense

15,225

 

15,979

EBITDA

83,288

 

69,493

    

EBITDA adjustments

   

Stock-based incentive compensation

5,988

 

4,178

Restructuring, acquisition, integration and other

4,496

 

4,111

Adjusted EBITDA

$          93,772

 

$          77,782

    
C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB